Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Depreciation & Amortization (CF) (2018 - 2025)

Serina Therapeutics' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $16000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 71.43% year-over-year to $16000.0; the TTM value through Sep 2025 reached $105000.0, down 27.08%, while the annual FY2024 figure was $194000.0, 115.56% up from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $16000.0 at Serina Therapeutics, roughly flat from $16000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $227000.0 in Q1 2021 and bottomed at $6000.0 in Q4 2023.
  • The 4-year median for Depreciation & Amortization (CF) is $21000.0 (2023), against an average of $46666.7.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 833.33% in 2024 before it plummeted 71.93% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $227000.0 in 2021, then tumbled by 97.36% to $6000.0 in 2023, then soared by 833.33% to $56000.0 in 2024, then tumbled by 71.43% to $16000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Depreciation & Amortization (CF) are $16000.0 (Q3 2025), $16000.0 (Q2 2025), and $17000.0 (Q1 2025).